{"changes":[],"country":"US","description":"Axonis Therapeutics develops drugs targeting KCC2, a brain protein central to neural inhibition, with lead candidate AXN-027 for epilepsy and chronic pain. It aims to treat patients with epilepsy, pain, and other central nervous system disorders. Its proprietary KCC2 discovery engine is built on research spun out of Boston Children's Hospital, Harvard, and Laval University.","domain":"axonistx.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotechnology","investors":[],"lat":42.3601,"lng":-71.0589,"location":"Boston, MA","name":"Axonis Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":115000000,"currency":"USD","date":"2024-10-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-18","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"axonistx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-18","status":"attributed","url":null},{"fact":"existence","publisher":"axonistx.com","retrievedAt":"2026-05-18","status":"self-reported","url":"https://axonistx.com"},{"fact":"description","publisher":"axonistx.com","retrievedAt":"2026-05-18","status":"self-reported","url":"https://axonistx.com"}],"stage":"series-a","techStack":[],"totalRaisedUsd":150000000,"updatedAt":"2026-05-18"}